NEOGEN CORP Stock: price and insider trades · United States · SEC (Form 4)Track the NEOGEN CORP share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, NEOGEN CORP has recorded 180 reports. Market capitalisation: €2.6bn. The latest transaction was reported on 20 August 2026 (Retenue fiscale). Among the most active insiders: ADENT JOHN EDWARD. Every trade is accessible without an account.
€130,663
9 ops.
Sell Volume
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,000 of 29,063 companies
FCF yld 1.3%
Earn yld -0.3%
EV/EBITDA 19.6x
ROE -0.4%
Gross mgn 47%
Net mgn -0.9%
Debt/EBITDA 4.7x
Pillars 2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 August 2026
All Executives180 Thresholds0 Prospectus0 Other0
Declarations 180 total
● Chief Accounting Officer · Executives · 19 Aug 2026
2,365 shares @ US$11.87 Restricted Stock Units SEC:0000711377-26-000020:0
● CEO · Executives · 19 Aug 2026
20,397 shares @ US$11.87 Restricted Stock Units SEC:0000711377-26-000019:0
◆ Chief Legal Officer · Executives · 14 Aug 2026
38,627 shares @ US$11.65 0.018% mcap 100.0% of flow Common Stock SEC:0000711377-26-000016:0
◆ Senior Vice President · Executives · 14 Aug 2026
25,751 shares @ US$11.65 0.012% mcap 44.8% of flow Common Stock SEC:0000711377-26-000017:0
◆ Chief Accounting Officer · Executives · 14 Aug 2026
8,584 shares @ US$11.65 0.0040% mcap 18.5% of flow Restricted Stock Units SEC:0000711377-26-000018:0
◆ CEO · Executives · 14 Aug 2026
141,631 shares @ US$11.65 0.066% mcap 62.3% of flow Common Stock SEC:0000711377-26-000014:0
◆ CFO · Executives · 14 Aug 2026
51,502 shares @ US$11.65 0.024% mcap 34.8% of flow Common Stock SEC:0000711377-26-000015:0
▲ CEO · Executives · 4 Aug 2026
370 shares @ US$11.81 0.0002% mcap 0.4% of flow Common Stock SEC:0000711377-26-000013:0
Canonical exit: 2 Nov 2026 (T+90) ● Former Officer · Executives · 3 Jun 2026
30,337 shares @ US$8.7866 0.012% mcap 11.9% of flow Common SEC144:0001959173-26-004307
▲ CEO · Executives · 17 Feb 2026
23 shares @ US$10.94 0.0% of flow Common Stock SEC:0000711377-26-000006:0
Canonical exit: 18 May 2026 (T+90) ▲ CEO · Executives · 26 Jan 2026
25 shares @ US$9.855 0.0% of flow Common Stock SEC:0000711377-26-000005:0
Canonical exit: 26 Apr 2026 (T+90) ◆ Senior Vice President · Executives · 7 Jan 2026
50,813 shares @ US$7.38 50.0% of flow Common Stock SEC:0000711377-26-000004:0
◆ Senior Vice President · Executives · 7 Jan 2026
50,813 shares @ US$7.38 50.0% of flow Common Stock SEC:0000711377-26-000003:0
▲ CEO · Executives · 16 Jan 2026
137 shares @ US$9.3349 0.1% of flow Common Shares SEC:0000711377-26-000001:0
Canonical exit: 16 Apr 2026 (T+90) ◇ Former CFO · Executives · 1 Dec 2025
12,912 shares @ US$5.98 2.1% of flow Common Stock SEC:0000711377-25-000077:0
▲ CEO · Executives · 3 Nov 2025
177 shares @ US$6.25 0.1% of flow Common Shares SEC:0000711377-25-000076:0
Canonical exit: 1 Feb 2026 (T+90) ◆ CFO · Executives · 3 Nov 2025
178,855 shares @ US$6.29 100.0% of flow Common Stock SEC:0000711377-25-000074:0
◇ Director · Executives · 27 Oct 2025
1,777 shares @ US$6.19 1.2% of flow Common Stock SEC:0000711377-25-000072:0
◇ Director · Executives · 27 Oct 2025
1,777 shares @ US$6.19 2.7% of flow Common Stock SEC:0000711377-25-000071:0
◇ Director · Executives · 27 Oct 2025
1,777 shares @ US$6.19 2.7% of flow Common Stock SEC:0000711377-25-000070:0
◇ Director · Executives · 27 Oct 2025
1,777 shares @ US$6.19 2.8% of flow Common Stock SEC:0000711377-25-000069:0
◇ Former CEO · Executives · 27 Oct 2025
38,759 shares @ US$6.19 4.2% of flow Common Stock SEC:0000711377-25-000062:0
● Former CEO · Executives · 27 Oct 2025
8,527 shares @ US$6.19 0.9% of flow Common Stock SEC:0000711377-25-000062:1
◇ Director · Executives · 27 Oct 2025
3,553 shares @ US$6.07 3.5% of flow Common Stock SEC:0000711377-25-000061:0
◇ Director · Executives · 27 Oct 2025
2,025 shares @ US$6.19 1.6% of flow Common Stock SEC:0000711377-25-000059:0
25 of 180 declarations
Load more (155 remaining) 关于 NEOGEN CORP Neogen Corp.(股票代码:NEOG)是一家在美国纳斯达克上市的公司,总部位于美国密歇根州兰辛市。Neogen成立于1982年,源于密歇根州立大学相关的科学研究工作,已从一家小型研究型初创公司发展成为食品安全和动物安全领域的全球专家。该公司目前为近40个国家的客户提供服务,其商业和运营足迹遍及北美、欧洲、拉丁美洲和亚太地区。([neogen.com](https://www.neogen.com/about/))
Neogen的业务围绕两个核心部门:食品安全和动物安全。食品安全部门包括用于检测过敏原、病原体、微生物和其他污染物,以及用于食品加工商和实验室的环境监测、微生物学和快速检测工具的解决方案。动物安全部门涵盖免疫分析试剂和检测试剂盒、动物毒理学产品、兽医仪器和耗材、动物护理和生物安全产品,以及用于牲畜和伴侣动物的基因组学服务。主要品牌包括Petrifilm、Clean-Trace、Molecular Detection System和Reveal。([neogen.com](https://www.neogen.com/about/))
从竞争角度来看,Neogen在诊断、生物安全和质量保证的交叉领域占据了专业利基市场。其模式受益于经常性消耗品、广泛的已安装客户群以及食品链中日益增长的监管需求。该公司的客户群从商业实验室到奶牛、肉牛、家禽和猪肉运营商,强化了与食品链合规性而非可自由支配支出相关的相对防御性需求状况。([neogen.com](https://www.neogen.com/about/))
从地理上看,Neogen仍以美国为中心,其公司总部位于密歇根州兰辛市Lesher Place 620号。同时,它在包括欧洲、加拿大、拉丁美洲和亚太地区在内的多个地区设有制造、行政、销售和服务基地。该公司还指出,其在美国、荷兰、英国和其他国际市场拥有制造和分销能力,这突显了其全球供应链覆盖范围。([neogen.com](https://www.neogen.com/4ac3cb/globalassets/pdfs/quarterly-and-annual-forms/fy2025-q4-10k.pdf))
近期公司发展主要集中在投资组合简化和资产负债表修复。Neogen于2025年7月完成了将其全球清洁剂和消毒剂业务剥离给Kersia Group的交易,交易金额为130亿美元现金,所得款项主要用于偿还债务。该公司还在2025年4月完成了其定期贷款和循环信贷额度的再融资,降低了借款利差并延长了到期日。在最新的年度报告中,管理层强调了3M食品安全交易后正在进行的整合工作,而2025财年收入为894.7亿美元,运营亏损仍然较高,反映了整合成本和重组行动。([sec.gov](https://www.sec.gov/Archives/edgar/data/711377/000095017025114388/neogen_fy25_annual_repor.pdf))
对于法语投资者而言,NEOG最好被视为一家专业的美国医疗保健相关工业技术公司,拥有有吸引力的终端市场,但仍在消化一项转型性收购并重塑其投资组合。对于关注转型的市场参与者而言,SEC Form 4内部人交易活动和公司治理披露仍然是相关的监测点。([neogen.com](https://www.neogen.com/4ac3cb/globalassets/pdfs/quarterly-and-annual-forms/fy2025-q4-10k.pdf))